2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenAnother positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏- ·17.7.How many shares do you have? I have 305 myself, this is one of my wildcards. When do you think one can expect results 1-2 years?
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
·2.7.I'm surprised by how the market reacts. I think they are showing really good signs and many things are going their way. Is it only when they make money that we will get a positive and directionally upward curve?
- ·30.6.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-provides-mid-business-113000239.html 1. Name change and new stock ticker (Rebranding) The company is completely changing its identity to better reflect its focus on central nervous system cancer (brain and spinal cord). New name: Plus Therapeutics changes its name to Cerenome. New ticker symbol: On the Nasdaq exchange, their symbol changes from PSTV to CNSY. When: The change takes effect on August 3, 2026. As a shareholder, no action is required; it happens automatically. 2. Status of cancer drug (REYOBIQ™) Their primary drug candidate, REYOBIQ, is progressing as planned in clinical trials: Brain tumors (Glioblastoma): The company has almost completed enrollment for its Phase 2 study (31 out of 34 patients are enrolled) and expects to hold an important status meeting with the US health authorities (FDA) afterwards to move closer to final approval. Pediatric cancer: They have received approvals to start a new study against pediatric brain cancer, where the first patients are expected to receive treatment in the third quarter of 2026. Production: The scaling up of production for commercial use is on schedule. 3. Commercial progress for test platform (CNSide®) Their diagnostic platform, CNSide (an advanced cerebrospinal fluid test to detect cancer spread), shows good commercial progress. The company has recently secured important coverage agreements with major US health insurers (including Elevance Health, Blue Shield of California, and Medicare approval), which makes it much easier to get the test to patients and secure revenue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenAnother positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏
- ·17.7.How many shares do you have? I have 305 myself, this is one of my wildcards. When do you think one can expect results 1-2 years?
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
- ·2.7.I'm surprised by how the market reacts. I think they are showing really good signs and many things are going their way. Is it only when they make money that we will get a positive and directionally upward curve?
- ·30.6.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-provides-mid-business-113000239.html 1. Name change and new stock ticker (Rebranding) The company is completely changing its identity to better reflect its focus on central nervous system cancer (brain and spinal cord). New name: Plus Therapeutics changes its name to Cerenome. New ticker symbol: On the Nasdaq exchange, their symbol changes from PSTV to CNSY. When: The change takes effect on August 3, 2026. As a shareholder, no action is required; it happens automatically. 2. Status of cancer drug (REYOBIQ™) Their primary drug candidate, REYOBIQ, is progressing as planned in clinical trials: Brain tumors (Glioblastoma): The company has almost completed enrollment for its Phase 2 study (31 out of 34 patients are enrolled) and expects to hold an important status meeting with the US health authorities (FDA) afterwards to move closer to final approval. Pediatric cancer: They have received approvals to start a new study against pediatric brain cancer, where the first patients are expected to receive treatment in the third quarter of 2026. Production: The scaling up of production for commercial use is on schedule. 3. Commercial progress for test platform (CNSide®) Their diagnostic platform, CNSide (an advanced cerebrospinal fluid test to detect cancer spread), shows good commercial progress. The company has recently secured important coverage agreements with major US health insurers (including Elevance Health, Blue Shield of California, and Medicare approval), which makes it much easier to get the test to patients and secure revenue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
2026 Q1 -tulosraportti
Vain PDF
69 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 14.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 15.5. | ||
Vuosittainen yhtiökokous 2026 14.5. | ||
2025 Q4 -tulosraportti 12.3. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenAnother positive news: The news is about the biotechnology company Plus Therapeutics (Nasdaq: PSTV) and their subsidiary CNSide Diagnostics, which has entered into a new regional agreement with the health insurance company Medical Mutual. Key points of the news: New coverage in the USA: The agreement came into effect on July 1, 2026, and provides health insurance coverage for approximately 1.2 million people in the states of Ohio and Kentucky. What is covered? The agreement covers the company's CNSide® test (Cerebrospinal Fluid Tumor Cell Enumeration Assay). It is a specialized laboratory test of cerebrospinal fluid (CSF) used to detect, quantify, and monitor cancer cells that have spread to the central nervous system (leptomeningeal metastases). Significant milestone: With this agreement, the CNSide test reaches a total contractual coverage of approximately 127 million people in the USA. Behind the technology and the company: The test enables doctors to diagnose faster and more accurately, tailor treatments, and monitor how cancer patients (especially with spread from breast cancer, lung cancer, or melanoma) respond to ongoing therapy. The agreement with Medical Mutual is another step in Plus Therapeutics' commercial rollout of CNSide in 2026, where they have secured agreements with both regional and national insurance companies (including Elevance Health, Blue Shield of California, and Highmark) during the year. https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-regional-coverage-113000620.html 🤝🙏
- ·17.7.How many shares do you have? I have 305 myself, this is one of my wildcards. When do you think one can expect results 1-2 years?
- ·14.7.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html Here's what the news means for you as an investor, broken down into the most critical points: 1. It removes the "bottleneck" for doctors The biggest problem for many biotech and diagnostics companies is not inventing a good product, but getting doctors to actually use it. Doctors slavishly follow clinical guidelines (like NCCN). Before: Doctors might have tested cerebrospinal fluid sporadically or given up because the old method was too uncertain. Now: NCCN guidelines now directly dictate that systematic testing should be done every 4 to 8 weeks during treatment. This creates a completely natural, recurring need for testing. 2. Enormous momentum for "Reimbursement" (Refusion) To make money from a medical test in the USA, insurance companies must pay for it. They typically refuse to pay if a test is not backed by official guidelines or solid data. The fact that NCCN now recommends more frequent testing makes it much easier for Plus Therapeutics to convince the remaining American insurance companies to cover CNSide. This directly supports their 2026 goal of reaching 150 million covered lives in the USA. 3. "The Razor and Blade" business model The most attractive thing about CNSide is that it is not a "one-and-done" test. Since the guidelines now recommend testing every 4-8 weeks to monitor if the treatment works, CNSide becomes a continuous revenue stream per patient. More tests per patient mean higher and more predictable revenue (recurring revenue) for the company. In short: The news significantly reduces clinical risk and paves the way for commercial growth in 2026. 🤝🤞
- ·2.7.I'm surprised by how the market reacts. I think they are showing really good signs and many things are going their way. Is it only when they make money that we will get a positive and directionally upward curve?
- ·30.6.https://finance.yahoo.com/healthcare/articles/plus-therapeutics-provides-mid-business-113000239.html 1. Name change and new stock ticker (Rebranding) The company is completely changing its identity to better reflect its focus on central nervous system cancer (brain and spinal cord). New name: Plus Therapeutics changes its name to Cerenome. New ticker symbol: On the Nasdaq exchange, their symbol changes from PSTV to CNSY. When: The change takes effect on August 3, 2026. As a shareholder, no action is required; it happens automatically. 2. Status of cancer drug (REYOBIQ™) Their primary drug candidate, REYOBIQ, is progressing as planned in clinical trials: Brain tumors (Glioblastoma): The company has almost completed enrollment for its Phase 2 study (31 out of 34 patients are enrolled) and expects to hold an important status meeting with the US health authorities (FDA) afterwards to move closer to final approval. Pediatric cancer: They have received approvals to start a new study against pediatric brain cancer, where the first patients are expected to receive treatment in the third quarter of 2026. Production: The scaling up of production for commercial use is on schedule. 3. Commercial progress for test platform (CNSide®) Their diagnostic platform, CNSide (an advanced cerebrospinal fluid test to detect cancer spread), shows good commercial progress. The company has recently secured important coverage agreements with major US health insurers (including Elevance Health, Blue Shield of California, and Medicare approval), which makes it much easier to get the test to patients and secure revenue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt